Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Minimal Optimal Dose of Sugammadex in Elective Surgery
NCT03515694Phase 4Completed
- Sponsor
- Erasmus Hospital
- Start
- Apr 2018
- Primary completion
- Sep 2018
- Modality
- Biodegradable Polymers, Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of Sugammadex in neuromuscular blockade (NMB), sponsored by Erasmus Hospital. Started Apr 2018; status: completed.
02
Drugs
Sugammadex
03
Conditions
neuromuscular blockade (NMB)
Beyond the preview
Go deeper on NCT03515694.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03515694.